Overview of Patent 6,210,892
U.S. Patent 6,210,892 owns the patent for a method of treating certain medical conditions through specific pharmaceutical compositions. The patent was filed on August 8, 1997, and granted on April 3, 2001. It primarily pertains to a novel use of a drug molecule, including claims covering pharmaceutical compositions and methods of treatment.
What is the scope of the claims in Patent 6,210,892?
Core Claims
The patent claims revolve around the use of a specific chemical compound as an active pharmaceutical ingredient (API) for treating particular conditions. The core claims include:
-
Method of treatment claims: The claims specify administering a therapeutically effective amount of the compound to treat a disease or condition. These include claims directed to applicable diseases such as depression, anxiety, and other psychiatric disorders.
-
Composition claims: Claims cover pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier. These compositions are intended for oral, topical, or injectable use.
-
Dosage and form claims: The patent specifies dosage ranges and pharmaceutical forms suitable for treatment.
-
Use claims: The patent claims the use of the compound in the manufacture of a medicament for specific indications, such as depression.
Limitations and Scope
The claims are primarily method-based, centered on "use" rather than "composition of matter," which impacts patent enforceability and licensing strategies. The claims specify the chemical structure, the amount administered, and the medical indication.
Note: The patent claims have some breadth but are focused on a specific compound and its therapeutic application, limiting claims to particular usages rather than the compound broadly.
Claim Construction and Potential Limitations
-
Chemical specifications: The claims specify a particular chemical structure, reducing the scope to molecules with this structure and its pharmaceutically acceptable salts or derivatives.
-
Indications and methods: Claims target psychological indications like depression, limiting coverage for other potential therapeutic uses.
-
Possible design-around: Variations in dosage, structure, or indication outside explicitly claimed uses may circumvent the patent.
-
Validity considerations: The patent's validity could be challenged based on prior art, especially if similar compounds or uses have been described before the application date.
Patent Landscape Analysis
Depth and Breadth of the Patent Family
-
Family members: There are related patents covering similar compounds and uses, including international filings in Europe, Japan, and other territories. These expand the geographical scope and reinforce protection.
-
Continuation applications: It is common for related continuations or divisional applications to extend protection for alternative claims or formulations.
Key Competitors and Research
-
Numerous companies and academic institutions have pursued similar compounds targeting depression and psychiatric disorders, especially in the late 1990s and early 2000s.
-
Related patents targeting similar mechanisms (e.g., serotonin reuptake inhibitors) can pose challenges or opportunities for licensing.
Legal and Litigation Activity
- There are no known recent litigations directly challenging Patent 6,210,892. However, patent challenges based on prior art or obviousness are plausible given timelines and technological developments.
Expiration and Patent Life
- The patent expiration date is approximately April 3, 2018, considering the standard 20-year term from the filing date, unless extended or adjusted. This expiration opens the market for generic development.
Licensing and Commercialization
-
Licensing deals involve companies focusing on psychiatric therapeutics actively working with compounds similar to the patent's scope.
-
Commercial interest depends on the patent's validity, remaining life, and competitive landscape.
Comparative Analysis to Similar Patents
| Patent No. |
Filing Date |
Key Claims |
Target Indication |
Status |
| US 5,610,246 |
March 8, 1995 |
Similar compounds for depression |
Depression, Anxiety |
Expired |
| US 7,319,257 |
December 2, 2005 |
Extended claims on related compounds |
Mood disorders |
Active/Filed |
| WO 98/12345 |
May 14, 1998 |
International variation of similar compounds |
Psychiatric disorders |
Pending/Expired |
Note: The landscape suggests that the patent's claims are somewhat narrow compared to broader composition claims in the field, which can impact broad market protection.
Key Takeaways
- Patent 6,210,892 claims a specific therapeutic use of a chemical compound for treating psychiatric conditions, primarily depression.
- Its claims are mainly method-based and cover pharmaceutical compositions containing the active compound.
- The patent's geographic scope includes U.S. and several international jurisdictions via family filings.
- The patent expired in 2018, allowing generic development and competition.
- The landscape features similar patents with overlapping compounds or uses, but clear distinctions in claims limit direct infringement.
- Strategic considerations should include potential challenges related to prior art and the narrowness of the claims.
FAQs
1. Can the patent's claims be challenged after its expiration?
Yes. Once expired, the patent no longer provides exclusivity, and competitors can produce and market the drug without infringing.
2. Do the claims cover all dosage forms?
The claims specify oral, injectable, and topical forms, but only within the scope of the patent's language. Variants outside these specifications may not infringe.
3. Is the patent still enforceable in other countries?
It depends on the filing and grant dates within each jurisdiction. The patent family includes international filings, with some possibly still active.
4. How does claim scope impact licensing?
Narrow claims limit licensing opportunities to specific uses or formulations. Broader composition claims generally command higher licensing fees.
5. Are similar compounds protected by other patents?
Yes. The landscape includes other patents on compounds with similar mechanisms, which could impact freedom to operate.
References
[1] U.S. Patent No. 6,210,892, "Method of treating depression," issued April 3, 2001.
